• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cellebrite Announces First-Quarter 2026 Results

    5/14/26 7:00:00 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology
    Get the next $CLBT alert in real time by email

    First-Quarter ARR Growth of 21% and TTM Free Cash Flow Margin of 32%

    Q2 Outlook Highlights ARR Acceleration

    TYSONS CORNER, Va. and PETAH TIKVA, Israel, May 14, 2026 /PRNewswire/ -- Cellebrite DI Ltd. (NASDAQ:CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced financial results for the three months ending March 31, 2026.

    Cellebrite Logo (PRNewsfoto/Cellebrite)

    "Cellebrite's first quarter of 2026 was highlighted by the delivery of a substantial slate of innovative offerings and new capabilities to the marketplace," stated Thomas E. Hogan, Cellebrite's CEO. "We are extremely pleased with the enthusiastic response from customers around the world to our new Guardian Investigate, Genesis, advanced unlock and drone forensics solutions. We delivered solid first-quarter 2026 results and are excited about our prospects to accelerate ARR expansion in the second quarter."

    First-Quarter 2026 Financial Highlights

    • Revenue of $128.3 million, up 19% year-over-year
    • Subscription revenue was $117.9 million, up 23% year-over-year
    • Total Annual Recurring Revenue (ARR) of $493.0 million, up 21% year-over-year
    • Recurring revenue dollar-based net retention rate of 115%
    • GAAP gross profit and gross margin of $105.9 million and 82.5%, respectively; Non-GAAP gross profit and gross profit margin of $110.2 million and 85.9%, respectively
    • GAAP net income of $10.9 million; Non-GAAP net income of $30.6 million
    • GAAP diluted earnings per share of $0.04; Non-GAAP diluted earnings per share of $0.12
    • Adjusted EBITDA and adjusted EBITDA margin of $30.6 million and 23.9%, respectively
    • Free cash flow for the trailing twelve months of $158.6 million, or 32.0% on a margin basis

    Recent Business Highlights

    Strategy

    • On March 1, 2026, Cellebrite closed its acquisition of SCG Canada Inc., a leading provider of hand-held digital forensics solutions that enable access to more than 80 of the most common Unmanned Aerial Vehicles (UAVs) for extraction, decoding and visualization of important forensic artifacts. This acquisition represented an important strategic step that broadened Cellebrite's digital forensics capabilities to include drones, an emerging device category that is seeing strong global growth across the defense, intelligence, law enforcement and commercial sectors as well as by bad actors. SCG's solution enables rapid access and visualization of mission-critical data at the point of collection, for quick decisions that can save lives. SCG's powerful drone forensic data extraction capability, combined with the portability of its offering, creates an additional new, rich data source to help power Cellebrite AI for enhanced decision making, especially in the field where speed is essential.

    Innovation

    • Cellebrite introduced early access to Cellebrite Genesis, a new purpose-built agentic AI product revolutionizing the way investigations are conducted. Cellebrite Genesis provides an intuitive, conversation-like experience to analyze mobile phone extractions, call detail records, documents, messages, images, video and more, turning them into immediate, actionable insights. Genesis can be deployed on its own or alongside other Cellebrite solutions to dramatically accelerate investigations across a wide variety of complex data sources, crime types and scenarios. Cellebrite Genesis offers customers instant delivery of transformational agentic AI with the precision, investigative rigor and public safety-grade guardrails investigators need to strengthen narcotics, human trafficking and crimes against children investigations among several other crime types as well as reinvigorate cold cases. Cellebrite Genesis is currently in beta testing.
    • Cellebrite announced the worldwide general availability of Guardian Investigate, a collaborative AI-powered investigative management solution that delivers a suite of capabilities for daily workflow collaboration across investigators, departments and agencies. Guardian Investigate centralizes digital evidence — including UFDR extractions, call detail records, documents and multimedia — into one secure workspace, enabling investigators to review evidence, manage tasks, build case narratives, and collaborate across departments and agencies in real time while maintaining chain of custody.
    • Cellebrite announced its Spring 2026 Release, highlighted by expanded device access capabilities across the widest range of iOS and Android devices and operating systems, including support for iPhone 17 and iOS 26. In addition, the Company highlighted emerging new use cases for Corellium by Cellebrite with automotive and industrialized systems manufacturers. By virtualizing Arm-based systems at the hardware level, Corellium enables automotive software teams to recreate and test complete vehicle environments in the cloud, from low-level controllers and safety-critical systems to autonomous driving compute to in-cabin and infotainment applications, at the speed of real silicon, without maintaining physical infrastructure.
    • Cellebrite announced last week that its Cellebrite Government Cloud (CGC) platform achieved FedRAMP® High Authorization, with the U.S. Department of Justice (DOJ) serving as the authorizing agency. This milestone authorization confirms that Cellebrite Government Cloud has met the federal government's most stringent cloud security requirements and is now available for government-wide adoption.

    Go-To-Market

    • From April 13 through April 17, 2026, Cellebrite hosted the 2026 C2C User Summit, its second annual user conference. This year's conference attracted hundreds of attendees from 30 countries, including customers from nearly 500 organizations spanning law enforcement, defense, intelligence and the private sector. The event was highlighted by powerful keynote speakers, deep-dive sessions, live demos, workshops and training courses as well as the Company's Digital Justice Awards. The awards, referred to as JUSTYS, was streamed live by the Law & Crime Network's YouTube channel and spanned 12 different categories, recognizing some of the best and brightest minds and sharpest technical skillsets in digital investigations in both the public and private sectors.

    Supplemental financial information can be found on the Investor Relations section of our website at https://investors.cellebrite.com/financial-information/quarterly-results. 

    Financial Outlook

    David Barter, Cellebrite's CFO, said, "Cellebrite's ARR growth in the first quarter demonstrated sequential stability as we executed well in anticipation of bringing to market so many new products and technologies. We're shifting gears to drive the second quarter with a myriad of exciting opportunities to accelerate our ARR, deliver strong operating results and generate healthy free cash flow." 

    The Company's second-quarter and full-year 2026 financial expectations are as follows:





    Second-Quarter 2026 Expectations



    Full-Year 2026 Expectations





    (as of 05/14/26)



    (as of 05/14/26)

    ARR



    $510 million - $513 million



    $567 million - $573 million

    Annual Growth



    22% - 23%



    18% - 19%

    Revenue



    $130 million - $133 million



    $565 million - $571 million

    Annual Growth



    15% - 17%



    19% - 20%

    Adjusted EBITDA



    $29 million - $31 million



    $149 million - $155 million

    Adjusted EBITDA margin



    22% - 23%



    26% - 27%

    Conference Call Information

    Cellebrite will host a live conference call and webcast later today to review the Company's first-quarter 2026 financial results and discuss its full-year 2026 outlook. Pertinent details include:

    Date:



    Thursday, May 14, 2026

    Time:



    8:30 a.m. ET

    Call-In Number:



    203-518-9814 / 800-274-8461

    Conference ID:



    CLBTQ126

    Event URL:



    https://investors.cellebrite.com/events/event-details/cellebrite-q1-2026-financial-results-conference-call-webcast 

    Webcast URL:



    https://edge.media-server.com/mmc/p/7b5rowvx

    In conjunction with the conference call and webcast, historical financial tables and supplemental data will be available on the quarterly results section of the Company's investor relations website at https://investors.cellebrite.com/financial-information/quarterly-results.

    Non-GAAP Financial Information and Key Performance Indicators

    This press release includes non-GAAP financial measures. Cellebrite believes that the use of non-GAAP cost of revenue, non-GAAP gross profit, non-GAAP operating expenses, non-GAAP operating income, non-GAAP net income, non-GAAP EPS and adjusted EBITDA is helpful to investors. These measures, which the Company refers to as its non-GAAP financial measures, are not prepared in accordance with GAAP.

    The Company believes that the non-GAAP financial measures provide a more meaningful comparison of its operational performance from period to period, and offer investors and management greater visibility into the underlying performance of its business:

    • Share-based compensation expenses utilize varying available valuation methodologies, subjective assumptions and a variety of equity instruments that can impact a company's non-cash expenses;
    • Acquired intangible assets are valued at the time of acquisition and are amortized over an estimated useful life after the acquisition;
    • Acquisition-related expenses and executive severance expenses relate to the cash component of contractual severance due to our former CFO, all of which are unrelated to current operations and neither are comparable to the prior period nor predictive of future results;
    • To the extent that the above adjustments have an effect on tax (income) expense, such an effect is excluded in the non-GAAP adjustment to net income;
    • Tax expense, depreciation and amortization expense vary for many reasons that are often unrelated to our underlying performance and make period-to-period comparisons more challenging; and
    • Financial instruments are remeasured according to GAAP and vary for many reasons that are often unrelated to the Company's current operations and affect financial income.

    Free cash flow is calculated as net cash provided by or used in operating activities less purchases of property and equipment. We believe that free cash flow is a useful indicator of liquidity that provides information to management and investors about the amount of cash provided by or used in our operations that, after the investments in property and equipment, can be used for strategic initiatives.

    Each of our non-GAAP financial measures is an important tool for financial and operational decision making and for evaluating our own operating results over different periods of time. The non-GAAP financial measures do not represent our financial performance under U.S. GAAP and should not be considered as alternatives to operating income or net income or any other performance measures derived in accordance with GAAP. Non-GAAP measures should not be considered in isolated from, or as an alternative to, financial measures determined in accordance with GAAP. Non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in our industry, as other companies in our industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, and exclude expenses that may have a material impact on our reported financial results. Further, share-based compensation expense has been, and will continue to be for the foreseeable future, significant recurring expenses in our business and an important part of the compensation provided to our employees. In addition, the amortization of intangible assets is expected to be a recurring expense over the estimated useful life of the underlying intangible asset and acquisition-related expenses will be incurred to the extent acquisitions are made in the future. Furthermore, foreign exchange rates may fluctuate from one period to another, and the Company does not estimate movements in foreign currencies.

    A reconciliation of each of these non-GAAP financial measures to their most comparable GAAP measure is set forth in a table included at the end of this press release, which is also available on our website at https://investors.cellebrite.com. 

    In regard to forward-looking non-GAAP guidance, we are not able to reconcile the forward-looking adjusted EBITDA measure to the closest corresponding GAAP measure without unreasonable efforts because we are unable to predict the ultimate outcome of certain significant items including, but not limited to, fair value movements, share-based payments for future awards, tax expense, depreciation and amortization expense, and certain financing and tax items.

    This press release also includes key performance indicators, including annual recurring revenue and dollar-based retention rate.

    Annual recurring revenue ("ARR") is defined as the annualized value of active term-based subscription license contracts and maintenance contracts related to perpetual licenses in effect at the end of that period. Subscription license contracts and maintenance contracts for perpetual licenses are annualized by multiplying the revenue of the last month of the period by 12. The annualized value of contracts is a legal and contractual determination made by assessing the contractual terms with our customers. The annualized value of maintenance contracts is not determined by reference to historical revenue, deferred revenue or any other GAAP financial measure over any period. ARR is not a forecast of future revenue, which can be impacted by contract start and end dates and renewal rates.

    Dollar-based net retention rate ("NRR") is calculated by dividing customer recurring revenue by base revenue. We define base revenue as recurring revenue we recognized from all customers with a valid license at the last quarter of the previous year period, during the four quarters ended one year prior to the date of measurement. We define our customer revenue as the recurring revenue we recognized during the four quarters ended on the date of measurement from the same customer base included in our measure of base revenue, including recurring revenue resulting from additional sales to those customers.

    References to Websites and Social Media Platforms

    References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

    Caution Regarding Forward Looking Statements

    This document includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "will," "appear," "approximate," "foresee," "might," "possible," "potential," "believe," "could," "predict," "should," "could," "continue," "expect," "estimate," "may," "plan," "outlook," "future" and "project" and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include, but are not limited to, estimated financial information for the second quarter of 2026 and for fiscal year 2026 including those statements with respect to our prospects to accelerate ARR expansion in the second quarter; the myriad of exciting opportunities to accelerate our ARR, deliver strong operating results and generate healthy free cash flow; and those statements regarding quarterly and full-year 2026 revenue and annual recurring revenue, profitability, earnings and free cash flow; as well as commentary associated with future performance, strategies, prospects, and other aspects of Cellebrite's business are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to: Cellebrite's ability to keep pace with technological advances and challenges and evolving industry standards with respect to software, artificial intelligence, or device access, to adapt to changing market potential within our markets and to successfully launch new solutions and add-ons that meet or exceed customer needs; our material dependence on the acceptance of our solutions by domestic and international law enforcement, public safety, defense and intelligence agencies; real or perceived errors, failures, defects or bugs in our solutions; licensing of technology from third parties, including our dependence on maintaining those licenses or seeking alternative solutions; failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; intense competition in all of our markets, including risks associated with pricing pressures from and loss of market share to competitors with greater resources than we have and increasing competition as a result of consolidation in the industry; the misuse of our solutions by our customers which may achieve suboptimal results or be perceived as incompatible with human rights; our ability to properly manage our growth as a business, and execute new offerings, developments and strategic opportunities, including joint ventures, partnerships and acquisitions; our dependence on our customers to renew their subscriptions and purchase additional subscriptions or services from us; the use of artificial intelligence in our digital investigation platform; challenges associated with large transactions, including with respect to longer sales cycles, as well as with developing, offering, implementing, and maintaining new solutions; risk of security vulnerabilities or defects, including cyber-attacks, information technology system breaches, failures or disruptions which are critical to our operations and maintaining the trust and confidence of our customers; risks associated with political, geo-political and reputational factors related to our business or operations, including Cellebrite operations in Israel and/or negative publicity, including with respect to the nature of our solutions; risks associated with our ability to obtain CFIUS approval for the acquisition of Corellium and with our ongoing compliance with national security agreements entered into with the U.S. government; risks that our intellectual property rights may not be adequate to protect our business or assets or that others may make claims on our intellectual property, claim infringement on their intellectual property rights, or claim a violation of their license rights, including relative to free or open-source-software components we may use risks relating to the regulatory constraints to which we are subject, including Israeli export laws, our compliance with such laws and related export licenses issued from the government of Israel;  risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer; risks associated with our significant international operations, including due to our Israeli operations, fluctuations in foreign exchange rates, rising global inflation, and exposure to regions subject to political or economic instability, including the State of Israel; uncertainties regarding the impact of changes in macroeconomic and/or global conditions, including as a result of slowdowns, recessions, economic instability, political unrest, or outbreaks of disease, as well as the resulting impact on information technology spending and government budgets, on our business and other factors, risks and uncertainties set forth in the section titled "Risk Factors" in Cellebrite's annual report on Form 20-F filed with the SEC on March 3, 2026, and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission ("SEC"), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

    About Cellebrite 

    Cellebrite's (Nasdaq: CLBT) mission is to protect communities, nations and businesses as a global leader in digital investigative and intelligence solutions. More than 7,000 global law enforcement agencies, defense and intelligence organizations and enterprises trust Cellebrite's AI-powered software portfolio to make forensically sound digital data more accessible and actionable. Cellebrite technology allows customers to accelerate nearly 3 million legally sanctioned investigations annually, enhance sovereign security, elevate operational efficacy and efficiency and enable advanced mobile research and application security. Available via cloud, on-premises and hybrid deployments, Cellebrite's technology enables its customers around the globe to advance their missions, elevate public safety and safeguard data privacy. To learn more, visit us at www.cellebrite.com and https://investors.cellebrite.com and find us on social media @Cellebrite.

    Contacts:

    Investors Relations

    Andrew Kramer

    Vice President, Investor Relations & Treasury

    investors@cellebrite.com

    +1 973.206.7760

    Media

    Victor Cooper

    Sr. Director of Corporate Communications + Content Operations

    Victor.cooper@cellebrite.com

    +1 404.804.5910

     

    Cellebrite DI Ltd. 

    First-Quarter 2026 Results Summary

    (U.S Dollars in thousands)





    For the three months ended



    March 31,



    2026



    2025









    Revenue

    128,301



    107,549

    Gross profit

    105,881



    90,059

      Gross margin

    82.5 %



    83.7 %

    Operating income

    9,119



    12,268

      Operating margin

    7.1 %



    11.4 %

    Net income

    10,938



    17,400

    Cash flow from operating activities                         

    19,885



    20,878









    Non-GAAP Financial Data:







    Operating income

    28,586



    21,971

      Operating margin

    22.3 %



    20.4 %

    Net income

    30,620



    26,179

    Adjusted EBITDA

    30,617



    23,676

    Adjusted EBITDA margin

    23.9 %



    22.0 %

     

    Cellebrite DI Ltd. 

    Condensed Consolidated Balance Sheets

    (U.S. Dollars in thousands)







    March 31,



    December 31,





    2026



    2025

    Assets









    Current assets









    Cash and cash equivalents



    $            133,689



    $            124,457

    Short-term deposits



    140,777



    161,049

    Marketable securities



    154,602



    151,544

    Trade receivables (net of allowance for credit losses of $423 and $506 as of March 31, 2026 and

    December 31, 2025, respectively)



    72,739



    104,972

    Prepaid expenses and other current assets



    25,799



    19,630

    Contract acquisition costs



    5,732



    6,595

    Inventories



    7,528



    7,603

    Total current assets



    540,866



    575,850











    Non-current assets









    Other non-current assets



    7,091



    14,618

    Marketable securities



    105,491



    97,959

    Deferred tax assets, net



    11,760



    10,880

    Property and equipment, net



    23,150



    22,209

    Operating lease right-of-use assets, net



    16,403



    16,308

    Intangible assets, net



    127,966



    81,469

    Goodwill



    119,559



    119,559

    Total non-current assets



    411,420



    363,002

    Total assets



    $            952,286



    $            938,852











    Liabilities and shareholders' equity









    Current Liabilities









    Trade payables



    $              10,868



    $               16,834

    Other accounts payable and accrued expenses



    79,652



    71,244

    Deferred revenues



    255,095



    277,583

    Operating lease liabilities



    4,596



    3,996

    Total current liabilities



    350,211



    369,657











    Long-term liabilities









    Other long-term liabilities



    23,179



    16,677

    Deferred revenues



    50,147



    49,526

    Operating lease liabilities



    18,209



    18,674

    Total long-term liabilities



    91,535



    84,877

    Total liabilities



    441,746



    454,534











    Shareholders' equity 









    Share capital



    *)



    *)

    Additional paid-in capital



    585,233



    568,721

    Treasury share, NIS 0.00001 par value; 41,776 ordinary shares



    (85)



    (85)

    Accumulated other comprehensive income



    992



    2,220

    Accumulated deficit



    (75,600)



    (86,538)

    Total shareholders' equity



    510,540



    484,318

    Total liabilities and shareholders' equity



    $            952,286



    $            938,852



    *) Less than 1 USD

     

    Cellebrite DI Ltd. 

    Condensed Consolidated Statements of Income

    (U.S Dollars in thousands, except share and per share data)





    For the three months ended



    March 31,



    2026



    2025









    Revenue:







    Subscription services

    $             96,549



    $             76,688

    Term-license

    21,304



    19,141

    Other non-recurring

    3,668



    4,411

    Professional services  

    6,780



    7,309

    Total revenue

    128,301



    107,549









    Cost of revenue:







    Subscription services

    14,238



    7,332

    Term-license

    —



    —

    Other non-recurring

    3,497



    3,301

    Professional services

    4,685



    6,857

    Total cost of revenue 

    22,420



    17,490









    Gross profit

    $            105,881



    $             90,059









    Operating expenses:







    Research and development, net

    35,872



    27,277

    Sales and marketing

    43,222



    38,768

    General and administrative

    17,668



    11,746

    Total operating expenses

    $              96,762



    $              77,791









    Operating income

    $                9,119



    $              12,268

    Financial income, net

    4,515



    7,060

    Income before tax

    13,634



    19,328

    Tax expense

    2,696



    1,928

    Net income

    $              10,938



    $              17,400









    Earnings per share







    Basic

    $                  0.04



    $                  0.07

    Diluted

    $                  0.04



    $                  0.07









    Weighted average shares outstanding







    Basic

    246,470,084



    237,246,654

    Diluted

    252,077,487



    249,302,220









    Other comprehensive (loss) income:







    Unrealized loss on hedging transactions

    (951)



    (779)

    Unrealized (loss) income on marketable securities               

    (819)



    64

    Currency translation adjustments

    542



    (481)

    Total other comprehensive loss, net of tax

    (1,228)



    (1,196)

    Total other comprehensive income

    $                9,710



    $             16,204









     

    Cellebrite DI Ltd.

    Condensed Consolidated Statements of Cash Flow

    (U.S Dollars in thousands, except share and per share data)







    For the three months ended





    March 31,





    2026



    2025











    Cash flow from operating activities:



















    Net income



    $             10,938



    $             17,400

    Adjustments to reconcile net income to net cash provided by operating activities:









    Share-based compensation and RSU's



    14,384



    8,777

    Amortization of premium, discount and accrued interest on marketable securities



    (1,148)



    (523)

    Depreciation and amortization



    7,005



    2,631

    Interest income from short-term deposits



    (1,793)



    (2,380)

    Deferred tax assets, net



    (750)



    (386)

    Decrease in trade receivables



    32,441



    1,721

    (Decrease) increase in deferred revenue



    (20,861)



    992

    Decrease in other non-current assets



    552



    785

    (Increase) decrease in prepaid expenses and other current assets



    (4,964)



    5,480

    Changes in operating lease right-of-use assets



    1,055



    1,156

    Changes in operating lease liability



    (1,015)



    (1,179)

    Decrease (increase) in inventories



    144



    (10)

    Decrease in trade payables



    (5,987)



    (1,046)

    Decrease in other accounts payable and accrued expenses



    (10,393)



    (12,152)

    Increase (decrease) in other long-term liabilities



    277



    (388)

    Net cash provided by operating activities



    19,885



    20,878











    Cash flows from investing activities:









    Purchases of property and equipment



    (3,041)



    (2,339)

    Cash paid in conjunction with acquisitions, net of acquired cash



    (15,278)



    —

    Purchase of Intangible assets



    (7,059)



    —

    Investment in marketable securities



    (74,575)



    (129,956)

    Proceeds from maturities of marketable securities



    24,607



    27,419

    Proceeds from sales of marketable securities



    39,706



    —

    Investment in short-term deposits



    (36,000)



    (84,000)

    Redemption of short-term deposits



    58,065



    62,372

    Net cash used in investing activities



    (13,575)



    (126,504)











    Cash flows from financing activities:



















    Exercise of options to shares



    2,128



    2,493

    Proceeds from Employee Share Purchase Plan



    1,383



    1,127

    Net cash provided by financing activities



    3,511



    3,620











    Net increase (decrease) in cash and cash equivalents



    9,821



    (102,006)

    Net effect of Currency Translation on cash and cash equivalents



    (589)



    822

    Cash and cash equivalents at beginning of period



    124,457



    191,659

    Cash and cash equivalents at end of period



    $            133,689



    $              90,475











    Supplemental cash flow information:









    Income taxes paid



    $                3,538



    $                   806

    Non-cash activities









    Operating lease liabilities arising from obtaining right-of-use assets



    $                1,150



    $                   813

     

    Cellebrite DI Ltd. 

    Reconciliation of GAAP to Non-GAAP Financial Information

    (U.S Dollars in thousands, except share and per share data)





    For the three months ended



    March 31,



    2026



    2025



    (Unaudited)



    (Unaudited)

    Cost of revenue

    $          22,420



    $          17,490

    Less:







    Share-based compensation

    692



    750

    Amortization of intangible assets

    3,612



    —

    Non-GAAP cost of revenue

    $          18,116



    $          16,740



















    For the three months ended



    March 31,



    2026



    2025



    (Unaudited)



    (Unaudited)

    Gross profit

    $         105,881



    $          90,059

    Share-based compensation

    692



    750

    Amortization of intangible assets

    3,612



    —

    Non-GAAP gross profit

    $         110,185



    $          90,809



















    For the three months ended



    March 31,



    2026



    2025



    (Unaudited)



    (Unaudited)

    Operating expenses

    $           96,762



    $           77,791

    Less:







    Share-based compensation

    13,692



    8,027

    Amortization of intangible assets

    1,362



    926

    Acquisition-related costs

    109



    —

    Non-GAAP operating expenses

    $           81,599



    $           68,838



















    For the three months ended



    March 31,



    2026



    2025



    (Unaudited)



    (Unaudited)

    Operating income

    $             9,119



    $           12,268

    Share-based compensation

    14,384



    8,777

    Amortization of intangible assets

    4,974



    926

    Acquisition-related costs

    109



    —

    Non-GAAP operating income

    $           28,586



    $           21,971



























    For the three months ended



    March 31,



    2026



    2025



    (Unaudited)



    (Unaudited)

    Net income

    $           10,938



    $           17,400

    Share-based compensation

    14,384



    8,777

    Amortization of intangible assets

    4,974



    926

    Acquisition-related costs

    109



    —

    Tax expense (income)

    215



    (924)

    Non-GAAP net income

    $           30,620



    $           26,179









    Non-GAAP Earnings per share:







    Basic

    $               0.12



    $               0.11

    Diluted

    $               0.12



    $               0.10









    Weighted average shares outstanding:               







    Basic

    246,470,084



    237,246,654

    Diluted

    259,252,345



    252,456,562



















    For the three months ended



    March 31,



    2026



    2025



    (Unaudited)



    (Unaudited)

    Net income

    $            10,938



    $          17,400

    Financial income, net

    (4,515)



    (7,060)

    Tax expense

    2,696



    1,928

    Share-based compensation

    14,384



    8,777

    Amortization of intangible assets

    4,974



    926

    Acquisition-related costs

    109



    —

    Depreciation expenses

    2,031



    1,705

    Adjusted EBITDA

    $           30,617



    $          23,676



















    For the three months ended



    March 31,



    2026



    2025



    (Unaudited)



    (Unaudited)

    Net cash provided by operating activities

    $           19,885



    $          20,878

    Less:







    Purchases of property and equipment

    (3,041)



    (2,339)

    Free cash flow

    $           16,844



    $          18,539

    Free cash flow margin

    13.1 %



    17.2 %

     

    Cellebrite DI Ltd. 

    Reconciliation of GAAP to Non-GAAP Financial Information

    (U.S Dollars in thousands, except share and per share data)





    For the trailing

    12 months

    ended



    For the three months ended



    March 31,



    March 31,



    December 31,



    September 30,



    June 30,



    2026



    2026



    2025



    2025



    2025



    (Unaudited)



    (Unaudited)



    (Unaudited)



    (Unaudited)



    (Unaudited)

    Net cash provided by operating activities

    $        172,551



    $          19,885



    $          86,811



    $          33,272



    $          32,583

    Less:



















    Purchases of property and equipment

    (13,927)



    (3,041)



    (3,956)



    (3,322)



    (3,608)

    Free cash flow

    $        158,624



    $          16,844



    $          82,855



    $          29,950



    $          28,975

    Free cash flow margin

    32.0 %



    13.1 %



    64.3 %



    23.8 %



    25.6 %

     

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cellebrite-announces-first-quarter-2026-results-302772161.html

    SOURCE Cellebrite

    Get the next $CLBT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLBT

    DatePrice TargetRatingAnalyst
    5/27/2026$20.00Buy
    DA Davidson
    3/28/2024$13.00 → $13.50Buy
    Needham
    3/13/2024Mkt Perform → Outperform
    William Blair
    2/16/2024$9.00 → $12.00Neutral → Buy
    BofA Securities
    7/19/2023$11.00Buy
    Craig Hallum
    8/12/2022$6.50 → $6.00Buy → Neutral
    BofA Securities
    8/12/2022Outperform → Mkt Perform
    William Blair
    2/24/2022$10.50Overweight
    JP Morgan
    More analyst ratings

    $CLBT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    DA Davidson initiated coverage on Cellebrite DI with a new price target

    DA Davidson initiated coverage of Cellebrite DI with a rating of Buy and set a new price target of $20.00

    5/27/26 9:01:30 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Needham reiterated coverage on Cellebrite DI with a new price target

    Needham reiterated coverage of Cellebrite DI with a rating of Buy and set a new price target of $13.50 from $13.00 previously

    3/28/24 8:25:08 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Cellebrite DI upgraded by William Blair

    William Blair upgraded Cellebrite DI from Mkt Perform to Outperform

    3/13/24 7:29:30 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    $CLBT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cellebrite Announces First-Quarter 2026 Results

    First-Quarter ARR Growth of 21% and TTM Free Cash Flow Margin of 32% Q2 Outlook Highlights ARR AccelerationTYSONS CORNER, Va. and PETAH TIKVA, Israel, May 14, 2026 /PRNewswire/ -- Cellebrite DI Ltd. (NASDAQ:CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced financial results for the three months ending March 31, 2026. "Cellebrite's first quarter of 2026 was highlighted by the delivery of a substantial slate of innovative offerings and new capabilities to the marketplace," stated Thomas E. Hoga

    5/14/26 7:00:00 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Cellebrite Announces Participation in Upcoming Investor Conferences

    TYSONS CORNER, Va. and PETAH TIKVA, Israel, May 8, 2026 /CNW/ -- Cellebrite DI Ltd. (NASDAQ:CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions, today announced that the Company plans to participate in the following investor conferences in May and June: Date: May 18, 2026Conference:J.P. Morgan 2026 Global Technology, Media and Communications ConferencePresentation Time3:30 p.m. ET Format:Fireside ChatCellebrite executive:   Thomas Hogan, chief executive officerDavid Barter, chief financial officerRoni Fialkov, senior vice president, global finan

    5/8/26 8:30:00 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Former Okta President of Auth0, Shiven Ramji, to Join Cellebrite as President, Products and Technology

    Ronnen Armon to RetireTYSONS CORNER, Va. and PETAH TIKVA, Israel, April 30, 2026 /CNW/ -- Cellebrite DI Ltd. (NASDAQ:CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions, today announced the appointment of Shiven Ramji as President of Products and Technology. In this role, Ramji will lead the Company's product and technology organization, driving innovation and execution of Cellebrite's industry-leading Digital Investigative and Intelligence platform. Ramji will start on May 4, 2026 and succeed Ronnen Armon, who will be retiring in a few months after the transition is complete.

    4/30/26 9:00:00 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    $CLBT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Marketing Officer Gee David Nicholas sold $74,477 worth of Ordinary shares (5,673 units at $13.13) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 142,032 units (SEC Form 4) (withholding tax)

    4 - Cellebrite DI Ltd. (0001854587) (Issuer)

    5/26/26 4:06:03 PM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Global Chief Revenue Officer Jewell Marcus sold $161,657 worth of Ordinary shares (12,658 units at $12.77), decreasing direct ownership by 3% to 440,101 units (SEC Form 4) to cover withholding tax

    4 - Cellebrite DI Ltd. (0001854587) (Issuer)

    5/19/26 8:39:36 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Chief Marketing Officer Gee David Nicholas sold $2,966 worth of Ordinary shares (228 units at $13.01), decreasing direct ownership by 0.15% to 147,705 units (SEC Form 4) to cover withholding tax

    4 - Cellebrite DI Ltd. (0001854587) (Issuer)

    5/14/26 4:08:02 PM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    $CLBT
    SEC Filings

    View All

    SEC Form 144 filed by Cellebrite DI Ltd.

    144 - Cellebrite DI Ltd. (0001854587) (Subject)

    5/21/26 4:49:21 PM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    SEC Form 144 filed by Cellebrite DI Ltd.

    144 - Cellebrite DI Ltd. (0001854587) (Subject)

    5/21/26 4:25:43 PM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    SEC Form 6-K filed by Cellebrite DI Ltd.

    6-K - Cellebrite DI Ltd. (0001854587) (Filer)

    5/14/26 7:15:15 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    $CLBT
    Leadership Updates

    Live Leadership Updates

    View All

    Former Okta President of Auth0, Shiven Ramji, to Join Cellebrite as President, Products and Technology

    Ronnen Armon to RetireTYSONS CORNER, Va. and PETAH TIKVA, Israel, April 30, 2026 /CNW/ -- Cellebrite DI Ltd. (NASDAQ:CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions, today announced the appointment of Shiven Ramji as President of Products and Technology. In this role, Ramji will lead the Company's product and technology organization, driving innovation and execution of Cellebrite's industry-leading Digital Investigative and Intelligence platform. Ramji will start on May 4, 2026 and succeed Ronnen Armon, who will be retiring in a few months after the transition is complete.

    4/30/26 9:00:00 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Cellebrite Appoints Holly Windham as General Counsel and Chief Compliance Officer

    TYSONS CORNER, Va. and PETAH TIKVA, Israel, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cellebrite DI Ltd (NASDAQ:CLBT), global leader in premier Digital Investigative and Intelligence solutions for the public and private sectors, today announced the appointment of Holly Windham as General Counsel and Chief Compliance Officer. Ms. Windham brings extensive legal leadership experience for growth-oriented technology companies with deep expertise spanning software, cloud platforms, cybersecurity, data privacy and public sector contracting – areas critical to Cellebrite's continued growth and market leadership. She will partner closely with Cellebrite's leadership team, overseeing all legal and complianc

    10/30/25 8:30:00 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Cellebrite to Acquire Corellium

    TYSONS CORNER, Va. and PETAH TIKVA, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ:CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced its agreement to acquire Corellium, a leader in Arm-based virtualization software. This combination will set a new standard for digital investigations and the security of smart devices including iOS, Android, automotive systems and any Arm-based IoT device. Customers across public safety, defense, intelligence and private sectors will benefit from: Accelerated identification of mobile vulnerabilities and exploitsIndustry-first ability to visualize and interact with virtual dev

    6/5/25 7:30:00 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    $CLBT
    Financials

    Live finance-specific insights

    View All

    Cellebrite Announces First-Quarter 2026 Results

    First-Quarter ARR Growth of 21% and TTM Free Cash Flow Margin of 32% Q2 Outlook Highlights ARR AccelerationTYSONS CORNER, Va. and PETAH TIKVA, Israel, May 14, 2026 /PRNewswire/ -- Cellebrite DI Ltd. (NASDAQ:CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced financial results for the three months ending March 31, 2026. "Cellebrite's first quarter of 2026 was highlighted by the delivery of a substantial slate of innovative offerings and new capabilities to the marketplace," stated Thomas E. Hoga

    5/14/26 7:00:00 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Cellebrite to Report First-Quarter 2026 Financial Results on May 14, 2026

    TYSONS CORNER, Va. and PETAH TIKVA, Israel, April 21, 2026 /CNW/ -- Cellebrite DI Ltd. (NASDAQ:CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced it will report its first-quarter 2026 financial results before the U.S. markets open on Thursday, May 14, 2026. Later that same morning, Cellebrite will host a live conference call and webcast to review the Company's financial results for the first quarter of 2026 and discuss its 2026 outlook. Relevant details include:Date:Thursday, May 14, 2026Time:

    4/21/26 8:30:00 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Cellebrite Announces Record Fourth-Quarter and Full-Year 2025 Results

    Total ARR grew 21% to $480.8 million; Revenue grew 18% to $128.8 million Net income of $21.3 million supports non-GAAP net income of $36.7 million and adjusted EBITDA of $38.3 million, 29.8% adjusted EBITDA margin TYSONS CORNER, Va. and PETAH TIKVA, Israel, Feb. 11, 2026 /PRNewswire/ -- Cellebrite (NASDAQ:CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced financial results for the three and twelve months ending December 31, 2025. "Cellebrite closed 2025 with a solid fourth quarter that capp

    2/11/26 7:00:00 AM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    $CLBT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Cellebrite DI Ltd.

    SC 13D/A - Cellebrite DI Ltd. (0001854587) (Subject)

    9/17/24 4:33:52 PM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by Cellebrite DI Ltd.

    SC 13D/A - Cellebrite DI Ltd. (0001854587) (Subject)

    8/29/24 6:07:01 PM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G/A filed by Cellebrite DI Ltd. (Amendment)

    SC 13G/A - Cellebrite DI Ltd. (0001854587) (Subject)

    3/12/24 12:38:56 PM ET
    $CLBT
    Computer Software: Prepackaged Software
    Technology